Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This clinical-stage biotech was one of April's brightest stars.

Why Brooklyn ImmunoTherapeutics Stock Crushed It in April

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics appoints Erich Mohr, Ph.D., ICD.D. to Board of Directors

Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics

An unknown biotech has turned its early investors into millionaires over the past month. Can it continue its momentum?

Up 1,300% in the Past Month, Is This Mysterious Biotech a Buy?

Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) is moving higher again on Monday morning as the stock continues to increase in popularity on the subreddit r/wallstreetbets. What Happened: The stock has soared over the last week after Reddit traders identified the stock as a low float high short interest short squeeze candidate.

Why Brooklyn ImmunoTherapeutics Is Surging Higher Again Today

The stock price of Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) increased from over 64% pre-market as it went from $49.80 to over $82 pre-market. This is why it happened.

BTX Stock: From $49.80 To Over $82 Pre-Market Explanation

Brooklyn Immuno Therapeutics Inc. (NYSE: BTX) shares are soaring Friday. The stock is likely continuing its run after the company paid $1 million towards the acquisition of a license for Factor Bioscience's and Novellus mRNA gene editing and cell therapies technology.

Brooklyn Immuno Therapeutics Skyrockets: Technical Levels To Watch

Today, investors in BTX stock appear to be on board in a big way with a major announcement from this hot meme stock and Reddit favorite. The post BTX Stock: The Big News That Has Brooklyn ImmunoTherapeutics Rocketing Higher appeared first on InvestorPlace.

BTX Stock: The Big News That Has Brooklyn ImmunoTherapeutics Rocketing Higher

The stock price of Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) increased from a previous close of $34.22 to a day high of $59.59. This is why it happened.

BTX Stock: From $34.22 To $59.59 Explanation

Shares of Brooklyn ImmunoTherapeutics have surged more than 800% over the past month despite a lack of a major catalyst that could explain the price jump on a fundamental basis.

Reddit Strikes Again: Why Is A Stock You Never Heard Of Skyrocketing In Value?

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Matthew During, M.D., Ph.D. to the Company's Scientific Advisory Board

Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics

The stock price of Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) increased by over 30% during intraday trading. This is why it happened.

BTX Stock: Over 30% Increase Intraday Explanation

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells

Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Dennis H. Langer to the Company's Board as an independent Director

Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc.

The stock price of Brooklyn Immunotherapeutics (NYSEAMERICAN: BTX) increased 27.33%. This is why it happened.

Brooklyn Immunotherapeutics Stock Price Increased 27.33%: Why It Happened

BTX stock is building on the hype of its recent reverse merger as the company announces its new CEO selection. The post BTX Stock: The Big News That Has Brooklyn ImmunoTherapeutics Racing Higher appeared first on InvestorPlace.

BTX Stock: The Big News That Has Brooklyn ImmunoTherapeutics Racing Higher

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics, Inc. announces the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer

Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.

NTN Buzztime

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) announced that it completed the reverse merger with NTN Buzztime. These are the details.

Brooklyn ImmunoTherapeutics Has Completed A Reverse Merger with NTN Buzztime

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

News for Brooklyn ImmunoTherapeutics Stock (BTX)